Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Blood Pressure Imbalances and Circulatory Shock01:24

Blood Pressure Imbalances and Circulatory Shock

795
Disorders affecting blood volume, vascular tone, or vascular function can disrupt vascular homeostasis, including conditions like hypertension, hemorrhage, and shock.
Blood Pressure: Hypertension and Hypotension
Normal blood pressure is 120/80 mm Hg. Elevated blood pressure is 120-129/under 80 mm Hg. Hypertension, warranting treatment at 130/80 mm Hg, is often asymptomatic and can lead to severe cardiovascular events, aneurysms, peripheral arterial disease, chronic renal disease, or cardiac...
795
Mitral Valve Prolapse III: Nursing Management01:19

Mitral Valve Prolapse III: Nursing Management

15
The nursing management of Mitral Valve Prolapse, or MVP, centers around patient education, symptom monitoring, and lifestyle modifications.Patient Education on MVP Diagnosis and Heredity: Nurses should provide comprehensive education about MVP, a condition where the mitral valve does not close appropriately during heartbeats. This education often includes the condition's pathophysiology, symptoms, and potential complications, like arrhythmias or mitral regurgitation. Though not fully...
15
Cardiopulmonary Resuscitation IV: Pharmacological Management01:25

Cardiopulmonary Resuscitation IV: Pharmacological Management

13
Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...
13
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

11
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
11
Imbalances in Cardiac Output01:26

Imbalances in Cardiac Output

1.4K
The heart's primary function is to pump blood throughout the body, maintaining a balance between blood sent out (cardiac output) and blood returning (venous return). If this balance is disrupted, it can result in congestive heart failure (CHF), a severe condition where the heart becomes an inefficient pump, leading to inadequate blood circulation.
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...
1.4K
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

16
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
16

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

European Society of Cardiology: cardiovascular disease statistics 2025.

European heart journal·2026
Same author

Renin-angiotensin-aldosterone system failure drives inappropriate vasodilation in cardiogenic shock: a hypothesis.

European heart journal·2026
Same author

Transplacental Antibody Transfer: Mechanisms, Pregnancy-Related Disruptions, and Emerging Experimental Models.

Antibodies (Basel, Switzerland)·2026
Same author

Post-certification competencies and cardiovascular care delivery.

European heart journal·2026
Same author

Clinical practice guideline implementation: challenges and solutions for improved cardiovascular care: A Report from the European Society of Cardiology Cardiovascular RoundTable.

European heart journal. Quality of care & clinical outcomes·2026
Same author

The Quantum Brain: The Untold Story of Docosahexaenoic Acid's Role in Brain Evolution, Biophysics, and Cognition.

International journal of molecular sciences·2025

Related Experiment Video

Updated: Jul 15, 2025

The Intra-Aortic Balloon Pump
06:13

The Intra-Aortic Balloon Pump

Published on: February 5, 2021

21.4K

Cardiogenic shock in pregnancy.

Orene Y O Greer1,2, Rathai Anandanadesan3,4, Nishel M Shah1,2

  • 1Division of Reproductive and Developmental Biology, Department of Metabolism, Digestion and Reproduction, Faculty of Medicine, Imperial College London, London, UK.

BJOG : an International Journal of Obstetrics and Gynaecology
|October 5, 2023
PubMed
Summary

Cardiac disease affects 1-4% of pregnancies, with cardiogenic shock (CS) posing a severe risk. Early recognition and management, including mechanical circulatory support (MCS), are crucial for improving outcomes in pregnant women with heart conditions.

Keywords:
The Society of Cardiovascular Angiography and Interventions (SCAI) classificationcardiac diseasecardiogenic shockextracorporeal membrane oxygenation (ECMO)maternal mortalitymechanical circulatory supportperipartum cardiomyopathypre-conception counsellingpregnancyspontaneous coronary artery dissection

More Related Videos

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock
06:10

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock

Published on: June 12, 2021

3.3K
Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock
07:39

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock

Published on: August 16, 2021

3.6K

Related Experiment Videos

Last Updated: Jul 15, 2025

The Intra-Aortic Balloon Pump
06:13

The Intra-Aortic Balloon Pump

Published on: February 5, 2021

21.4K
Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock
06:10

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock

Published on: June 12, 2021

3.3K
Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock
07:39

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock

Published on: August 16, 2021

3.6K

Area of Science:

  • Cardiology
  • Maternal-Fetal Medicine
  • Critical Care Medicine

Background:

  • Cardiac disease complicates 1%-4% of pregnancies worldwide, particularly in low and middle-income countries (LMICs).
  • Rising maternal age, obesity, and comorbidities like pre-eclampsia contribute to acquired cardiovascular disease in pregnancy.
  • Increased survival rates for congenital heart disease (CHD) mean more women with CHD are becoming pregnant.

Purpose of the Study:

  • To review recent advancements in the classification of cardiogenic shock (CS).
  • To explore adaptations of CS classification for improved outcomes in pregnant women.
  • To highlight the importance of early recognition and management of cardiac disease during pregnancy.

Main Methods:

  • Narrative review of recent developments in cardiogenic shock classification.
  • Analysis of how CS classifications can be applied to pregnant populations.
  • Discussion of management strategies including mechanical circulatory support (MCS).

Main Results:

  • Cardiogenic shock (CS) in pregnancy is associated with significant mortality and morbidity.
  • Effective management hinges on early recognition and intervention for reversible causes.
  • Individualized care plans and adherence to guidelines have improved clinical outcomes.

Conclusions:

  • Adapting current CS classifications may enhance the management of pregnant women at risk.
  • Prompt diagnosis and timely intervention are critical for mitigating the risks of CS in pregnancy.
  • Further research into tailored CS management strategies for pregnant individuals is warranted.